Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Melissa H, Smith"'
Publikováno v:
Cancer Medicine Journal. 3:75-84
Background: Somatostatin Analogues (SSAs) are used to treat Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and acromegaly. Side effects of SAAs usually include biliary disorders, gastrointestinal disorders, injection-site pain and hyperglyce
Publikováno v:
Archives of medical case reports
Background: Fluoropyrimidines compose the backbone of regimens to treat many common solid tumors, including gastrointestinal (GI), breast and head/neck. As we continue to use these agents routinely, recognition of rare but real toxicities, such as ca
Publikováno v:
JOP
BACKGROUND: Pancreatectomy offers only potential for cure but is only possible in a minority of patients. Even in those patients who receive adjuvant chemotherapy, majority of them succumb to death due to metastases. Radiation Therapy Oncology Group
Publikováno v:
Cancer Med J
BACKGROUND: Most common sites of metastases in patients with colorectal cancer (CRC) include liver and lung. Brain metastases are very rare but their presence is associated with a poor prognosis and shorter survival. We report our investigation into
Publikováno v:
Cancer Med J
BACKGROUND: Somatostatin Analogues (SSAs) are used to treat Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and acromegaly. Side effects of SAAs usually include biliary disorders, gastrointestinal disorders, injection-site pain and hyperglyce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::89be9e5be4f9117d9b6af1d8db1652c7
https://europepmc.org/articles/PMC7219785/
https://europepmc.org/articles/PMC7219785/
Autor:
Valerie Relias, Kevin P. Daly, Barbara Weinstein, Muhammad Wasif Saif, Melissa H Smith, Julie Fu
Publikováno v:
Journal of Pancreatic Cancer, Vol 4, Iss 1, Pp 64-71 (2018)
Journal of Pancreatic Cancer
Journal of Pancreatic Cancer
Objective: To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. Materials and Methods: This retrospective chart review examined lanreotide depot/autoge
Publikováno v:
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: 5-fluorouracil (5-FU) and mitomycin-C (MMC) with radiotherapy (RT) remain an established treatment for patients with anal cancer (AC). Genetic mutations in two major metabolizing enzymes for 5-FU; dihydropyrimidine dehydrogenase ( DPYD an
Publikováno v:
Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology
Imatinib, an orally administered protein-tyrosine kinase inhibitor (TKI) is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Severe hepatotoxicity associated with imatinib is rare, and relations
Autor:
Zhenyang Jiang, Muhammad Wasif Saif, Marie C Garcon, Harriet Butler-Bowen, Melissa H Smith, Valerie Relias, Teresa Rodriguez
Publikováno v:
Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology
Background Fatigue is a common but devastating symptom for advanced pancreatic cancer (APC) patients. To date, no proven treatment exists. Methylphenidate (MPH) showed inconsistent results in treating other cancer related fatigue. We performed a retr
Autor:
Nausheen Hakim, Antonia Maloney, Jyothi Jose, Linda Moriarty, Wasif M. Saif, Jeffrey Chi, Danielle K. DePeralta, Gary B. Deutsch, Melissa H Smith, Sandeep Anantha, Arvind Rishi, Hasan Rehman, Elliot Newman, Gene F. Coppa, William Nealon
Publikováno v:
Journal of Clinical Oncology. 38:4628-4628
4628 Background: ESPAC-4 study showed that GemCap conferred a survival benefit over gemcitabine monotherapy in resected PC patients. ESPAC-4 included patients with median age of 65 years (37-81) and ECOG performance status (PS) of 0 (43%), 1 (54%) an